News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Astellas (ALPMY) Release:First Patient Dosed In Phase III MORPHO Trial Evaluating Gilteritinib As Maintenance Therapy Following Hematopoietic Stem Cell Transplant In Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia 8/22/2017
Alliance Foundation Trials Opens Global Trial Investigating First-In-Class Palbociclib In HR+, HER2+ Metastatic Breast Cancer 8/22/2017
These 3 Biotechs Could Have the Most Exciting Late-Stage Cancer Candidates 8/22/2017
BioLineRx Announces Regulatory Submission Of Phase III Registrational Study For BL-8040 In Stem Cell Mobilization 8/21/2017
Janssen Pharmaceutical Release: New XARELTO (Rivaroxaban) Data At ESC Congress 2017 Includes Late-Breaking Results From Landmark Phase III COMPASS Study 8/21/2017
Boehringer Ingelheim: Advancing Anticoagulation Care With New Data At ESC Congress 2017 8/21/2017
Argos (ARGS) Announces Interim Analysis Of Phase III ADAPT Trial To Be Presented At ESMO 2017 Congress 8/21/2017
Immatics Initiates Personalized Adoptive Cellular Therapy In Patients With Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse 8/21/2017
Tonix Pharma (TNXP) To Present Additional Phase II Clinical Results And Design Of Ongoing Phase III Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium 8/21/2017
Saniona's Partner, Productos Medix, S.A de S.V, Initiates Phase III Study For Tesofensine In Obesity 8/21/2017
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Highlight Commitment To Reducing The Risk Of Stroke Caused By Non-Valvular Atrial Fibrillation (NVAF) And Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) At ESC Congress 2017 8/18/2017
Ritter Pharma Announces Phase III Plans After Its End Of Phase II Meeting With FDA On RP-G28 For Lactose Intolerance 8/18/2017
Mithra Pharmaceuticals Announces First Subject Completes Estelle Phase III Study 8/18/2017
Amgen (AMGN) Release: Repatha (Evolocumab) Phase III Cognitive Function Study Results Published In The New England Journal of Medicine 8/17/2017
New Data Shows Previously Allergic Children Still Able To Tolerate Peanut Four Years After Treatment With A Novel Immunotherapy Licensed By Prota Therapeutics 8/17/2017
Biogen (BIIB) Gained $1 Billion Overnight After Becoming Goldman Sachs' Favorite Biotech 8/17/2017
Novo Nordisk A/S (NVO)’s Diabetes Drug Beats Out Eli Lilly (LLY)’s Trulicity in Phase III Trials 8/17/2017
Bristol-Myers Squibb (BMY)'s Stock Topples as Kidney Cancer Drug Flunks Phase III Study 8/16/2017
Lexicon Pharma (LXRX), Sanofi (SNY) Tout More Positive Phase III Diabetes Drug Data 8/15/2017
Ophthotech (OPHT)'s Wet AMD Drug Fails to Meet Primary Endpoint in Phase III Study 8/15/2017
Regeneron (REGN) Jumps Despite Ditching Development Of RSV Med 8/14/2017
CEL-SCI (CVM) Rockets As The FDA Removes Hold On Phase III Head & Neck Cancer Trial 8/14/2017
Spectrum Pharma (SPPI) Announces Initiation Of The Registrational Phase III Trial Of Qapzola (Apaziquone) In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) 8/14/2017
FDA Removes Clinical Hold On CEL-SCI (CVM)’s Phase III Head & Neck Cancer Trial 8/14/2017
Anthera Announces RESULT Phase III Clinical Study Of Sollpura Will Be Included In The European Cystic Fibrosis Clinical Trial Network 8/14/2017
Evoke Pharma (EVOK) Initiates Comparative Exposure Pharmacokinetic Study For Gimoti 8/14/2017
Hemispherx (HEB) Human Safety Study Of Intranasal Ampligen With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated 8/14/2017
GlaxoSmithKline (GSK) Ditches Ionis Pharma (IONS)'s Inotersen and IONIS-FB-LRx 8/11/2017
Here’s Why Sucampo (SCMP) Paid $200M For Its PhIII Niemann-Pick Drug 8/11/2017
Heron (HRTX) Announces Initiation Of Phase III Program For HTX-011 In Postoperative Pain Following Successful End-Of-Phase II Meeting With FDA 8/10/2017
Apellis Pharma Nabs $60 Million to Advance APL-2 into Phase III Trials 8/10/2017
Ocugen, Inc. Receives FDA Orphan Drug Designation For OCU300 (Brimonidine Tartrate) For The Treatment Of Ocular Graft Versus Host Disease 8/9/2017
Motif BioSciences, Inc.’s Second Phase 3 Clinical Trial In ABSSSI Finishes Patient Treatment Phase 8/9/2017
Motif BioSciences, Inc.’s Second Phase III Clinical Trial In ABSSSI Finishes Patient Treatment Phase 8/9/2017
CytoDyn (CYDY) Provides Update On Enrollment In Its Pivotal Phase Ib/III HIV Combination Trial 8/9/2017
Anika Therapeutics (ANIK) Announces Publication Of Data Demonstrating The Efficacy And Safety Of HYALOFAST In Combination With Stem Cells For The Treatment Of Cartilage Lesions On The Knee 8/8/2017
Aimmune (AIMT)’ Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy 8/8/2017
DURECT (DRRX) Release: ORADUR-Methylphenidate ER Capsule Achieves Primary Endpoint In Phase III Study In ADHD In Taiwan 8/8/2017
Starpharma Shares Jumped on Phase III Results of Vivagel 8/7/2017
Can-Fite BioPharma (CFBI) Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson 8/7/2017
Rebiotix Announces First Patient Enrolled In Phase III Clinical Trial Of RBX2660 For The Prevention Of Recurrent Clostridium Difficile Infection 8/7/2017
Biohaven (BHVN) Completes Randomization In Phase II/III Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 8/7/2017
Strongbridge Biopharma Provides Updates On KEVEYIS Launch And Recent Business Highlights, And Reports Second Quarter 2017 Financial Results 8/7/2017
MiMedx Files With The FDA To Initiate Its Investigational New Drug Achilles Tendonitis Phase III Clinical Trial 8/7/2017
Data Monitoring Committee Completes Mid-Study Review Of Celsion (CLSN)’s Phase III ThermoDox OPTIMA Study In Primary Liver Cancer 8/7/2017
Clearside Biomedical (CLSD) Announces Completion Of Patient Enrollment In Pivotal Phase III PEACHTREE Clinical Trial Of CLS-TA For Suprachoroidal Administration In Patients With Macular Edema Associated With Non-Infectious Uveitis 8/7/2017
Athersys (ATHX) Reports Alignment Of Key Regulators For Pivotal Registration Study In Stroke 8/7/2017
Ritter Pharma Reports Further Analysis From Its Phase IIb/III Trial Results Demonstrating Significant Reductions In Lactose Intolerance Symptoms 8/4/2017
Primary Endpoint Met in Eli Lilly (LLY)'s Phase III Trial for Migraine Drug Lasmiditan 8/4/2017
FDA Grants Orphan Drug Designation To Omeros (OMER)’ OMS721 For Treatment Of IgA Nephropathy 8/4/2017
Biofrontera AG Agrees With U.S. FDA On Ameluz Development Plan To Treat Basal Cell Carcinoma 8/4/2017
Korea's ViroMed Starts Trial Of Gene Therapy For Diabetic Foot Ulcers 8/4/2017
FDA Grants Genentech (RHHBY)’s Alecensa Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer 8/3/2017
MiMedx Initiates Phase III Plantar Fasciitis Clinical Trial 8/3/2017
BioMarin (BMRN) Announces Plans To Progress Both The 6e13vg/Kg And 4e13 Vg/Kg Doses Of BMN 270, Its Investigational Gene Therapy For Hemophilia A, Into Phase III Studies 8/3/2017
Roche (RHHBY)’s Tecentriq Hits Trouble with NICE in Bladder Cancer 8/3/2017
Foamix Pharma (FOMX) Announces Dosing Of First Patient In Third Phase III Acne Study For Minocycline Foam FMX101 8/3/2017
VM BioPharma Announces First Patient Dosed In Phase III Study Of Gene Therapy Candidate VM202 For Non-Healing Diabetic Foot Ulcers 8/3/2017
Hutchison China MediTech (Chi-Med)'s Innovative Drug Portfolio: Eight Candidates In 31 Trials 8/3/2017
Aclaris (ACRS) Submits Marketing Authorization Application In Europe For A-101 40% Topical Solution As A Novel Treatment For Seborrheic Keratosis 8/3/2017
AMAG (AMAG) Completes Feraheme (Ferumoxytol) FDA Submission For The Treatment Of All Adult Patients With Iron Deficiency Anemia 8/3/2017
FDA Calls AstraZeneca PLC (AZN) and MedImmune (AZN)’s Imfinzi a Breakthrough 8/2/2017
Geron (GERN) Under Pressure as Clinical Trial Changes Causes Delays 8/2/2017
CTI BioPharma Announces Completion Of Enrollment In The Phase III PIX306 Trial Of PIXUVRI For Aggressive B-Cell Non-Hodgkin Lymphoma 8/2/2017
Helsinn And MEI Pharma (MEIP) Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 8/2/2017
FDA Agrees to Critical Changes to CorMedix (CRMD)'s Phase III Study for Neutrolin 8/2/2017
DBV Tech Initiates Phase III Study Of Viaskin Peanut In Peanut-Allergic Patients One To Three Years Of Age 8/2/2017
Sandoz Canada Release: Sandoz Erelzi (Etanercept) Receives Positive Reimbursement Recommendation From Common Drug Review For Treatment Of Multiple Inflammatory Diseases 8/2/2017
Milestone Pharma Banks $55M, Advances Etripamil into Phase III and Expands Headcount 8/1/2017
Spectrum Pharma (SPPI) Announces Completion Of Enrollment In The Phase III Pivotal Study (ADVANCE) Of ROLONTIS (Eflapegrastim), A Novel Long-Acting GCSF 8/1/2017
GenSight Completes Enrollment Of RESCUE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 8/1/2017
Lexicon Pharma (LXRX) Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 Diabetes 8/1/2017
AcelRx (ACRX) Succeeds in ZALVISO Phase 3 IAP312 Study on Device Functionality 8/1/2017
Kitov (KTOV) Submits New Drug Application To FDA For KIT-302 8/1/2017
TG Therapeutics (TGTX) Announces Special Protocol Assessment (SPA) Agreement With The FDA For A Phase III Program Of TG-1101 (Ublituximab) For Patients With Multiple Sclerosis (MS) 8/1/2017
Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS) Ink Pact to Marry Their PD-1/PARP Drugs in Phase II and III 8/1/2017
FDA Panel Votes to Recommend Dynavax (DVAX)'s Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline (GSK)'s Engerix-B 7/31/2017
Why AstraZeneca PLC (AZN)'s MYSTIC Trial Failure May be a Bad Sign for Bristol-Myers Squibb (BMY) 7/31/2017
Biohaven (BHVN) Initiates Second Pivotal Phase III Clinical Trial Of Oral CGRP Antagonist For The Acute Treatment Of Migraine 7/31/2017
Amgen (AMGN) And Allergan (AGN) Submit Biosimilar Biologics License Application For ABP 980 To FDA 7/31/2017
Amgen (AMGN) Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 7/31/2017
Indivior Announces FDA Acceptance With Priority Review Designation Of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) For The Treatment Of Opioid Use Disorder 7/31/2017
Recro Pharma (REPH) Submits New Drug Application For IV Meloxicam 30mg 7/31/2017
Diffusion Pharma Selects Contract Research Organization For Phase III Clinical Trial Of Lead Compound TSC For Inoperable GBM Brain Cancer 7/31/2017
RedHill Biopharma (RDHL) Announces Unanimous Positive DSMB Recommendation For Continuation Of The Phase III Study With RHB-104 For Crohn’s Disease 7/31/2017
AstraZeneca PLC (AZN) Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints 7/28/2017
Evofem Announces First Patient Enrolled In A Phase III Clinical Trial Of AMPHORA (L-Lactic Acid, Citric Acid, And Potassium Bitartrate) For Prevention Of Pregnancy 7/28/2017
Galderma Announces Enrollment Of First Patient In Phase IIb Nemolizumab Trial In Atopic Dermatitis 7/28/2017
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/27/2017
Death Count Rises for Patients on Dynavax (DVAX)'s Hep B Vaccine But Overall Rate Was Low, Says the FDA 7/27/2017
Dr. Reddy's Laboratories Ltd. (RDY)’s And CHD Bioscience Announce Global License And Commercialization Agreement For Phase III Clinical Trial Candidate For Mitigation Of Surgical Site Infections 7/27/2017
AstraZeneca PLC (AZN) Release: TAGRISSO (Osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer 7/27/2017
Soligenix (SNGX) Initiates Pivotal Phase III Clinical Trial Of SGX942 (Dusquetide) For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 7/27/2017
Akcea Therapeutics And Ionis Pharma (IONS) Announce Submission Of Marketing Authorization Application For Volanesorsen To The EMA 7/27/2017
Positive Phase III Results Of Genentech (RHHBY)’s Actemra (Tocilizumab) For The Treatment Of Giant Cell Arteritis Published In The New England Journal of Medicine 7/27/2017
RegeneRx Biopharmaceuticals, Inc. (RGRX) Updates On RGN-259 Phase 3 Dry Eye Trial 7/27/2017
Eli Lilly (LLY) Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs 7/26/2017
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End 7/26/2017
BioCardia Completes Roll-In Cohort In Pivotal Phase III CardiAMP Heart Failure Trial 7/26/2017
TetraPhase (TTPH) Announces Positive Top-Line Results From Phase III IGNITE4 Clinical Trial In Complicated Intra-Abdominal Infections 7/26/2017
Merck & Co. (MRK) Dealt Another Setback as Its Ace Keytruda Comes Up Short in Head and Neck Cancer Study 7/26/2017
Boehringer Ingelheim Starts Clinical Study On Interchangeability Between Its Adalimumab Biosimilar Candidate And U.S.-Formulated Humira 7/26/2017
BioPharm Executive: And So It Continues: Let's Get Rid of Clinical Trials (Part 2) 7/26/2017
Alimera Sciences (ALIM) Announces Real-World Audit Data Supporting The Positive Benefits Of ILUVIEN Treatment 7/26/2017
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline 7/25/2017
Massachusetts’ Histogenics Looks to NeoCart for Replacing Knee Cartilage Loss 7/25/2017
BrainStorm Cell Announces Agreement With University of California, Irvine Medical Center To Participate In Phase III Trial Of NurOwn In ALS 7/25/2017
Eisai Inc. (ESALF.PK) Submits Supplemental New Drug Application To FDA For Lenvatinib In First-Line Hepatocellular Carcinoma 7/25/2017
Resverlogix (RVX.TO) Receives Approval Pathway From The FDA As To The Inclusion Of USA Patients In The Phase III BETonMACE Trial 7/25/2017
Neuronix Ltd. Announces The First Group Of Mild To Moderate Alzheimer Patients To Be Successfully Treated By The Neuroad Therapy System In London 7/25/2017
Janssen-Cilag International NV (JNJ) Announces Phase III Pivotal Study Results for Darunavir-Based Complete Treatment Regimen 7/25/2017
The Medicines Company (MDCO) Announces TANGO-2 Trial Of Meropenem-Vaborbactam (Formerly, Carbavance) Stopped Early For Superior Benefit-Risk Compared To Best Available Therapy For CRE 7/25/2017
Merck & Co. (MRK)'s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint Of Non-Inferiority To Efavirenz, Both In Combination With Other Antiretroviral Agents, In Pivotal Phase III Trial For Treatment Of HIV-1 Infection 7/25/2017
Retrophin (RTRX) Commences Patient Dosing In International, Registrational Phase III Trial Of RE-024 In PKAN 7/25/2017
Pacira (PCRX) Announces Topline Phase III Results For EXPAREL As A Single-Dose Nerve Block 7/25/2017
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer 7/24/2017
San Diego's Cytori (CYTX) Plunges Scleroderma Med Flunks Phase III Study 7/24/2017
Biohaven (BHVN) Enrolls First Patient In Pivotal Phase III Clinical Trial Of Oral Rimegepant For The Acute Treatment Of Migraine 7/24/2017
Shionogi Announces Positive Top-Line Results For S-033188 Phase III Study (CAPSTONE-1) In Otherwise Healthy Influenza Patients 7/24/2017
Data Put A Dent In Ironwood (IRWD)'s Expansion Plans 7/24/2017
Stealth Biotherapeutics Initiates Phase II/III Study of Elamipretide In Patients With Barth Syndrome 7/24/2017
Tocagen Receives EMA Priority Medicines (PRIME) Designation For Toca 511 In High Grade Glioma 7/24/2017
Pfizer (PFE) Announces Positive Top-Line Results From The Comparative REFLECTIONS B7391003 Study For PF-06439535, A Potential Biosimilar To Avastin 1 (Bevacizumab) 7/24/2017
Gilead (GILD) Boosted By New Late-Stage HIV Data 7/24/2017
Merck & Co. (MRK)'s Once-Daily HIV Drug Works Just As Well As Twice-Daily Formulation 7/24/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
SillaJen And Lee's Pharmaceutical Announce Approval By The China CFDA To Commence Phase III Clinical Trial For Oncolytic Immunotherapy, Pexa-Vec, In Liver Cancer 7/21/2017
BrainStorm Cell Awarded $16 Million Non-Dilutive Grant From CIRM In Support Of Phase III Clinical Trial Of NurOwn In ALS 7/21/2017
Amgen (AMGN) Release: FDA Accepts Biologics License Application For Aimovig (erenumab) 7/21/2017
FDA Accepts Biologics License Application For AMG 334 (Erenumab), An Important Regulatory Milestone For Novartis AG (NVS) 7/21/2017
Lexicon Pharma (LXRX) Collaborator Ipsen (IPN.PA) Receives Positive CHMP Opinion For Xermelo (Telotristat Ethyl) 7/21/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy 7/21/2017
Diffusion Pharma Achieves Drug Production Milestone For Planned Phase III Clinical Trial In Inoperable GBM Brain Cancer 7/20/2017
Trevena (TRVN) To Host 2017 Analyst Day And Announce Results Of ATHENA Open Label Safety Study Of OLINVO 7/20/2017
Kamada (KMDA) Submits Proposed Phase III Protocol To FDA For Inhaled Alpha-1 Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency Disease 7/20/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space 7/20/2017
U.S. FDA Grants Orphan-Drug Designation To Astellas (ALPMY) For Development Of FLT3 Inhibitor Gilteritinib In Acute Myeloid Leukemia 7/20/2017
Theravance Biopharma (TBPH) AndMylan (MYL) Announce Positive Results From 12-Month Phase III Safety Study Of Revefenacin (TD-4208) In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/20/2017
Incyte (INCY) Announces First Patient Treated In Phase III Clinical Trial Of Itacitinib For Acute Graft-Versus-Host Disease 7/20/2017
Aerie (AERI) Reports Positive Roclatan™ (Netarsudil/Latanoprost Ophthalmic Solution) 0.02%/0.005% Phase III 12-Month Topline Safety Results 7/20/2017
Evolus Announces EMA Acceptance For Review Of The Marketing Authorization Application For DWP-450 Neuromodulator 7/20/2017
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec 7/18/2017
BrainStorm Cell Announces Agreements With Massachusetts General Hospital And California Pacific Medical Center To Participate In Phase III Trial Of NurOwn In ALS 7/18/2017
DelMar Pharma Announces Completion Of First Site Initiation Visit For STAR-3 Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 7/18/2017
PTC Therapeutics (PTCT) Announces Publication Of Data From ACT DMD In The Lancet 7/18/2017
Paratek Pharma (PRTK)'s Antibiotic Meets All Endpoints in Late-Stage Study 7/18/2017
Abeona Therapeutics Receives Guidance From FDA To Commence Pivotal Phase III For EB-101 Gene Therapy For Patients With Epidermolysis Bullosa 7/18/2017
Leading Retinal Specialists To Highlight pSivida (PSDV)’s Durasert For Treatment Of Posterior Segment Uveitis At Prestigious Ophthalmology Conferences 7/18/2017
Bay Area's Nektar Therapeutics (NKTR) Comes Back With Impressive Opiod Addiction Study Data 7/18/2017
Novartis AG (NVS) Confirms 5 Year Data For First And Only Fully-Human IL-17A Inhibitor Cosentyx Reinforcing Sustained Efficacy And Safety Profile In Psoriasis 7/17/2017
No Relief For Investors As The FDA Keeps Partial Hold On Repros Therapeutics (RPRX)'s Proellex Program 7/17/2017
Spark Therapeutics (ONCE) Announces Publication In The Lancet Of Pivotal Phase III Clinical Trial Data For Investigational Voretigene Neparvovec 7/14/2017
Mallinckrodt (MNK) Phase III Terlipressin Trial Achieves Its Enrollment Target Ahead Of Schedule 7/14/2017
GENFIT (ALGFT) – The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date! 7/14/2017
Horizon Pharma (HZNP) Announces Four Poster Presentations On PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules At Cystinosis Research Network 2017 Family Conference 7/14/2017
Why This Bay Area Pharma Could Win the Hemophilia Race With 'One And Done' Drug 7/13/2017
Amgen (AMGN) Release: Second Phase III Study Shows Kyprolis (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma 7/13/2017
Bio Products Laboratory Presents New Phase III Data Demonstrating Prophylactic Coagadex (Coagulation Factor X, Human) Dosing Prevents Or Reduces Bleeding Episodes In Children With Moderate To Severe Hereditary Factor X Deficiency 7/12/2017
CSL Behring Release: New Data Demonstrate Prophylactic Treatment With IDELVION Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B 7/12/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease 7/12/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease 7/12/2017
Innovate Biopharmaceuticals Submits Orphan Drug Application To FDA For Pediatric Ulcerative Colitis Indication 7/12/2017
Vifor Pharma Announces Three Outcomes Trials In Heart Failure And Iron Deficiency 7/12/2017
Boehringer Ingelheim Release: Final Phase III Study Results Reinforces Safety And Efficacy Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017
Boehringer Ingelheim Release: Final Phase III Study Results Confirm Benefit Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017
ProMetic Life Sci (PFSCF.PK) Announces Positive Long Term Clinical Data On Ryplazym In Plasminogen Congenital Deficiency And Provides Regulatory Update 7/11/2017
Could Alnylam (ALNY) Have An Edge On This Smaller Biotech In Rare Disease? 7/11/2017
Oramed (ORMP) Announces End-Of-Phase II Meeting With FDA To Initiate Phase III Program 7/11/2017
Teva (TEVA) And The Huntington Study Group Announce Publication Of Data For AUSTEDO (Deutetrabenazine) Tablets In Huntington Disease From ARC-HD Study In JAMA Neurology 7/11/2017
Resverlogix (RVX.TO) And Hepalink Start Taiwan/China Trial Of CVD/Diabetes Treatment 7/11/2017
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online 7/10/2017
Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial 7/10/2017
Exelixis (EXEL) And Bristol-Myers Squibb (BMY) Initiate Phase III Trial Of Opdivo In Combination With CABOMETYX Or Opdivo And Yervoy In Combination With CABOMETYX, Versus Sunitinib In Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma 7/10/2017
Genentech (RHHBY) Shows Off Phase III Hemophilia A Data 7/10/2017
Ionis Pharma (IONS) Release: New Data Presented At Peripheral Nerve Society Meeting Further Support Potential Benefit Of Inotersen 7/10/2017
Anthera Pharma (ANTH) Announces RESULT Phase III Clinical Study Of Sollpura Will Be Included In The Cystic Fibrosis Foundation Therapeutics Development Network 7/10/2017
Allergan (AGN) Reports New Data Reinforcing The Effectiveness Of Viberzi (Eluxadoline) To Treat The Symptoms Associated With Irritable Bowel Syndrome With Diarrhea (IBS-D), Abdominal Pain And Diarrhea 7/10/2017
Pluristem Therapeutics (PSTI) Advances Its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation At 40 Active Sites By The End Of 2017 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
Prima Biomed (PRR.AX) Announces Approval For The Initiation Of The ‘INSIGHT’ Clinical Trial 7/10/2017
Mark Your Calendars: 7 Biotechs Facing Important Catalysts in July 7/7/2017
Alnylam (ALNY) And Sanofi Genzyme (SNY) Initiate ATLAS Phase III Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors 7/7/2017
Puma Biotech (PBYI) Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial 7/7/2017
Novan To Present Safety And Efficacy Data For SB204 Program In Adolescents At 13th World Congress Of Pediatric Dermatology 7/7/2017
Patient Deaths Prompt the FDA to Suspend Three of Merck & Co. (MRK)'s Keytruda Trials 7/7/2017
Bristol-Myers Squibb (BMY)'s Opdivo Prevails in Phase III Melanoma Trial 7/6/2017
3 Biotechs With Bulging Pipelines That Could Also Become Attractive Takeover Targets 7/6/2017
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug 7/6/2017
China FDA Approves CTAs For BeyondSpring’s Second Global Plinabulin Registrational Trial For Chemotherapy-Induced Neutropenia Prevention 7/6/2017
Anthera Announces Expansion Of Screening In European Sites In Phase III RESULT Clinical Study Of Sollpura 7/6/2017
Novo Nordisk A/S (NVO) Release: Results From SWITCH Trials For Tresiba Published In The Journal Of The American Medical Association 7/6/2017
Tonix Pharma (TNXP) Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For TNX-102 SL (Cyclobenzaprine HCL Sublingual Tablets) For The Treatment Of PTSD 7/6/2017
Ferring Pharma Announces New Analysis Of Rekovelle Data Relating To Personalised Medicine In Fertility Patients 7/5/2017
Worldwide Clinical Trials Selected By BrainStorm Cell As CRO For Phase III NurOwn Trial In ALS 7/5/2017
Biogen (BIIB)'s SPINRAZA (nusinersen) Receives Notice Of Compliance From Health Canada For The Treatment Of 5q Spinal Muscular Atrophy (SMA) 7/5/2017
Aimmune (AIMT) Enrolls First Patient In ARTEMIS (ARC010) European Phase III Clinical Trial Of AR101 For The Treatment Of Peanut Allergy 7/5/2017
Auris Med (EARS) Completes Enrollment Of Phase III Healos Trial Of Am-111 For The Treatment Of Sudden Deafness 7/5/2017
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon 7/5/2017